Rubicon Research Q4 FY26: Growth stays strong as capacity constraints shift the margin mix

Rubicon Research closed Q4 FY26 with a sharp step-up in scale and profitability. Consolidated revenue from operations rose to INR 5,139 million in the quarter, up 43.5% year on year. EBITDA increased faster at INR 1,213 million, up 67.2%, while PAT more than doubled to INR 768 million.

For FY26, the company reported revenue from operations of INR 17,540 million, EBITDA of INR 4,080 million and PAT of INR 2,467 million. The numbers reflect a business that has continued to broaden its portfolio while funding R&D and capacity additions through a mix of accruals and a strengthened balance sheet after the October 2025 IPO.

Q4 FY26: Broad-based growth, steady EBITDA guidance

Management described the quarter’s performance as broad based, supported by established products as well as newer launches. Product concentration remains contained within a familiar band. The top five products contributed 39% of Q4 revenue and the top ten contributed 57%. Pricing was described as stable, supported by the company’s focus on specialty and differentiated products.

A key operating feature for the quarter was the mix impact on gross margins. Gross margin eased marginally to 66.3% in Q4 from 66.5% in Q3. Management linked this to stronger than anticipated demand coupled with internal manufacturing capacity constraints, which increased reliance on outsourced manufacturing.

Despite this, Rubicon reiterated its operating EBITDA margin guidance range of 22% to 23%. Operating EBITDA margin stood at 23.1% in Q4.

Metric	Q4 FY26	Q4 FY25	YoY growth	FY26	FY25	YoY growth
Revenue from operations (INR million)	5,139	3,581	43.5%	17,540	12,843	36.6%
EBITDA (INR million)	1,213	726	67.2%	4,080	2,679	52.3%
PAT (INR million)	768	362	111.8%	2,467	1,344	83.6%
R&D expense (INR million)	594	361	NA	1,935	1,325	NA
Operating EBITDA margin (%)	23.1%	20.2%	NA	22.8%	20.6%	NA

Capacity and margins: outsourcing now, Pithampur later

Rubicon made a clear link between demand strength, its capex philosophy, and the current margin mix. Management stated that it prefers capex to lag demand. When demand comes in stronger than expected, the company uses outsourcing to protect customer supply and product sales, even if this pressures gross margins in the short term.

The company expects the higher-than-anticipated reliance on outsourced manufacturing to continue for at least a couple of quarters. It also indicated that tactical measures are being evaluated to reduce outsourcing over a two to three quarter timeframe. The key medium-term lever is the Pithampur site.

Rubicon said it has qualified the Pithampur facility and filed products with the USFDA, and is awaiting an inspection date. It expects to ramp up production from Pithampur in Q1 calendar year 2027. Management described the Pithampur ramp as gross margin accretive, since higher in-house production should reduce reliance on outsourced manufacturing.

In the earnings call, management added that the general block at Pithampur has enough demand to be filled and that the company expects to reach decent capacity utilization within 12 to 18 months after inspection, with ramp-up managed carefully from a quality standpoint.

R&D as a lead indicator: productivity metrics and spend plan

Rubicon continues to position R&D as a leading indicator for future revenue. R&D spending in Q4 FY26 was 11.6% of operating revenue, and 11.0% for the full year.

The company uses an internal R&D productivity construct: incremental revenue over a three-year period compared against lagging nine-quarter R&D spending. It reported the multiple improving from 3.3x in FY24 to 4.1x in FY25 and 5.9x in FY26.

Management reiterated that it remains on track for guided R&D spending of INR 5,000 million plus over nine quarters covering FY26, FY27 and Q1 FY28, with the full amount expensed through the P&L. In the call, management said a 5x plus productivity assumption is fair based on recent trends, while also expressing intent to improve further.

Arinna acquisition: India entry through a CNS platform

In April 2026, Rubicon acquired 85% of Arinna Lifesciences, a CNS-focused India formulations company. The investor presentation disclosed an enterprise value of INR 200 crore on a cash and debt free basis, with Rubicon paying INR 176 crore for its stake at INR 158.53 per share.

Arinna brings an India commercial platform with 60 brands, around 160 sales representatives, three divisions, 5,000 plus pharmacies, 600 plus stockists, and 4,000 active prescribers across 23 states. Management positioned the transaction as therapy-led rather than a geographic shift, describing India as an additional market to monetize Rubicon’s pipeline in its chosen CNS focus.

Rubicon also laid out a phased roadmap for Arinna. Phase 1 involves putting growth drivers in place. Phase 2 aims to deliver revenue growth that outperforms the Indian pharma market. Phase 3 focuses on profitability. Management stated confidence in beating IPM growth in FY28 and clarified that its consolidated EBITDA margin guidance already incorporates the lower EBITDA of Phase 1 and Phase 2.

Cash flows, balance sheet and shareholder actions

Rubicon ended FY26 with shareholders’ funds of INR 12,888 million and borrowings of INR 2,594 million, lower than the prior year. Cash and cash equivalents stood at INR 3,460 million as of 31 March 2026, including other bank balances.

FY26 cash flow from operations after tax was INR 2,050 million. Q4 operating cash flow after tax was INR 656 million, despite a large income tax payment of INR 501 million in the quarter.

Investing outflows in FY26 were INR 4,097 million, driven by the Pithampur acquisition, bank deposits, capex and other inorganic investments. On financing, management noted that finance costs may not necessarily decline because Arinna was partly funded through debt and factoring costs are part of the finance line.

The board recommended a dividend of 150%, equivalent to INR 1.50 per share, which management said corresponds to around a 10% payout ratio. The company also announced a proposal to create an ESOP pool, subject to shareholder approval, with the P&L impact already factored into EBITDA guidance.

Takeaways

Rubicon’s Q4 FY26 commentary reflects a company balancing rapid growth with capacity realities. Demand strength is pushing near-term outsourcing, which can weigh on gross margins, but management has held its operating EBITDA margin guidance range.

The next operational milestone is the USFDA inspection and subsequent ramp-up at Pithampur, which management expects to be margin accretive. In parallel, R&D intensity and disclosed productivity metrics remain central to the company’s long-term narrative, while the Arinna acquisition provides a new commercialization channel in India’s CNS market.